We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+33.44%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$962M
AUM Growth
-$17.7M
Cap. Flow
-$105M
Cap. Flow %
-10.94%
Top 10 Hldgs %
42.32%
Holding
98
New
25
Increased
18
Reduced
27
Closed
25

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$20.8M
2
SGMT icon
Sagimet Biosciences
SGMT
+$19.9M
3
ASND icon
Ascendis Pharma A/S
ASND
+$19.1M
4
CELC icon
Celcuity
CELC
+$16.5M
5
ORKA
Oruka Therapeutics
ORKA
+$13.5M

Top Sells

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$57.9M
2
NUVL
Nuvalent
NUVL
+$36.4M
3
DNTH icon
Dianthus Therapeutics
DNTH
+$23.1M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$18.5M
5
KOD icon
Kodiak Sciences
KOD
+$17.3M

Sector Composition

Rank Sector Weight
1 Healthcare 91.68%
2 Miscellaneous 6.61%
3 Financials 1.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGON icon
76
CG Oncology
CGON
$6.59B
– –
-166,349
Closed -$11.3M
CLDX icon
77
Celldex Therapeutics
CLDX
$3.07B
– –
-178,378
Closed -$5.66M
CMPX icon
78
CALL
Compass Therapeutics
CMPX
$432M
– –
-172,400
Closed -$912K
CMPX icon
79
Compass Therapeutics
CMPX
$432M
– –
-859,049
Closed -$4.54M
CNTA
80
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-466,345
Closed -$18.5M
CYTK icon
81
Cytokinetics
CYTK
$10B
– –
-71,203
Closed -$4.69M
EWTX icon
82
Edgewise Therapeutics
EWTX
$4.64B
– –
-42,615
Closed -$1.34M
FULC icon
83
Fulcrum Therapeutics
FULC
$294M
– –
-419,949
Closed -$2.55M
KALV
84
DELISTED
KalVista Pharmaceuticals
KALV
– –
-2,876,407
Closed -$57.9M
MNPR icon
85
Monopar Therapeutics
MNPR
$751M
– –
-43,488
Closed -$2.38M
NMRA icon
86
Neumora Therapeutics
NMRA
$261M
– –
-818,156
Closed -$1.6M
NUVL
87
DELISTED
Nuvalent
NUVL
– –
-354,914
Closed -$36.4M
NXTC icon
88
NextCure
NXTC
$27.9M
– –
-176,057
Closed -$1.88M
QURE icon
89
CALL
uniQure
QURE
$3.38B
– –
-500,000
Closed -$8.18M
REPL icon
90
Replimune Group
REPL
$1.46B
– –
-171,936
Closed -$1.32M
SRRK icon
91
Scholar Rock
SRRK
$7.04B
– –
-339,613
Closed -$16.7M
SRZN icon
92
Surrozen
SRZN
$264M
– –
-144,255
Closed -$4.2M
XNTK icon
93
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2B
– –
-825,000
Closed -$105M
ZURA icon
94
Zura Bio
ZURA
$548M
– –
-560,651
Closed -$3.34M
CLYM
95
Climb Bio
CLYM
$837M
– –
-684,908
Closed -$4.69M
RADX
96
Radiopharm Theranostics
RADX
$34.8M
– –
-187,406
Closed -$806K
AARD
97
Aardvark Therapeutics
AARD
$127M
– –
-33,684
Closed -$127K
GENB
98
Generate Biomedicines
GENB
$1.97B
– –
-100,000
Closed -$1.25M
1 2 3
4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Silverarc Capital Management held 98 positions worth $962M, down 1.8% from $980M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Silverarc Capital Management withdrew a net $105M in Q2 2026, closing 25 positions and reducing 27 holdings. Its most notable exit was KalVista Pharmaceuticals, an estimated $57.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 85% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Silverarc Capital Management opened a new position in Enliven Therapeutics worth $24.8M.

  • Silverarc Capital Management's largest Q2 2026 buy was Enliven Therapeutics: 489,382 shares worth $24.8M.
  • Silverarc Capital Management added most to Ascendis Pharma A/S in Q2 2026, an estimated $19.1M increase.
  • Silverarc Capital Management's biggest Q2 2026 reduction was Dianthus Therapeutics, cutting an estimated $23.1M.
  • Silverarc Capital Management fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $57.9M.
  • Silverarc Capital Management's ten largest holdings make up 42% of its $962M portfolio in Q2 2026.
  • Silverarc Capital Management opened 25 new positions and closed 25 in Q2 2026.
  • Silverarc Capital Management's portfolio value fell 1.8% quarter-over-quarter to $962M.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.